摘要
二甲双胍是Ⅱ型糖尿病的一线治疗药物.近期研究发现二甲双胍可以上调细胞周期蛋白CycG2,诱导线粒体介导的活性氧（ROS）的积累,从而抑制转化生长因子β（TGF-β）的活性.二甲双胍尚可保护非糖尿病乳腺癌转移,并可能成为乳腺癌的化学预防药物.文章将从基础和临床研究方面阐明二甲双胍对乳腺癌的抑制机制以及其耐药的相关研究.
Metformin is a first-line drug treatment for typeⅡdiabetes. Recent studies have showed that metformin can upregulate CycG2, induce mitochondria-mediated accumulation of reactive oxygen species （ROS）, and inhibit the activity of transforming growth factor-β （TGF-β）. Metformin could protect metastasis of nondiabetic breast cancer, and may become a chemopreventive drug for breast cancer. This review aims to clarify the inhibitory mechanism of metformin on the breast cancer and the drug resistance of metformin according to basic and clinical study.
出处
《肿瘤研究与临床》
CAS
2017年第10期717-720,共4页
Cancer Research and Clinic
关键词
乳腺肿瘤
二甲双胍
糖尿病
研究
Breast neoplasms
Metformin
Diabetes mellitus
Research
